image
Healthcare - Biotechnology - NASDAQ - CH
$ 41.63
1.37 %
$ 3.6 B
Market Cap
-8.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CRSP stock under the worst case scenario is HIDDEN Compared to the current market price of 41.6 USD, CRISPR Therapeutics AG is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CRSP stock under the base case scenario is HIDDEN Compared to the current market price of 41.6 USD, CRISPR Therapeutics AG is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CRSP stock under the best case scenario is HIDDEN Compared to the current market price of 41.6 USD, CRISPR Therapeutics AG is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRSP

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
35 M REVENUE
-90.57%
-467 M OPERATING INCOME
-109.66%
-366 M NET INCOME
-138.43%
-143 M OPERATING CASH FLOW
45.17%
-280 M INVESTING CASH FLOW
-74.87%
332 M FINANCING CASH FLOW
429.78%
0 REVENUE
0.00%
-148 M OPERATING INCOME
-129.80%
-136 M NET INCOME
-264.49%
-53.9 M OPERATING CASH FLOW
-7.83%
-19.8 M INVESTING CASH FLOW
-18.67%
10.6 M FINANCING CASH FLOW
-37.26%
Balance Sheet CRISPR Therapeutics AG
image
Current Assets 1.94 B
Cash & Short-Term Investments 1.9 B
Receivables 25 M
Other Current Assets 8.31 M
Non-Current Assets 305 M
Long-Term Investments 0
PP&E 278 M
Other Non-Current Assets 27.3 M
84.92 %12.38 %Total Assets$2.2b
Current Liabilities 87.8 M
Accounts Payable 14.7 M
Short-Term Debt 17.3 M
Other Current Liabilities 55.8 M
Non-Current Liabilities 222 M
Long-Term Debt 206 M
Other Non-Current Liabilities 15.8 M
4.75 %5.58 %18.00 %66.59 %5.09 %Total Liabilities$310.0m
EFFICIENCY
Earnings Waterfall CRISPR Therapeutics AG
image
Revenue 35 M
Cost Of Revenue 0
Gross Profit 37.3 M
Operating Expenses 504 M
Operating Income -467 M
Other Expenses -100 M
Net Income -366 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)35m037m(504m)(467m)100m(366m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
106.61% GROSS MARGIN
106.61%
-1333.05% OPERATING MARGIN
-1333.05%
-1046.43% NET MARGIN
-1046.43%
-18.96% ROE
-18.96%
-16.34% ROA
-16.34%
-21.70% ROIC
-21.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CRISPR Therapeutics AG
image
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -366 M
Depreciation & Amortization 19.3 M
Capital Expenditures -1.9 M
Stock-Based Compensation 86.6 M
Change in Working Capital 156 M
Others -57.3 M
Free Cash Flow -145 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CRISPR Therapeutics AG
image
Wall Street analysts predict an average 1-year price target for CRSP of $75.7 , with forecasts ranging from a low of $59 to a high of $100 .
CRSP Lowest Price Target Wall Street Target
59 USD 41.72%
CRSP Average Price Target Wall Street Target
75.7 USD 81.87%
CRSP Highest Price Target Wall Street Target
100 USD 140.21%
Price
Max Price Target
Min Price Target
Average Price Target
1001009090808070706060505040403030Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership CRISPR Therapeutics AG
image
Sold
0-3 MONTHS
1 M USD 5
3-6 MONTHS
3.5 M USD 3
6-9 MONTHS
2.74 M USD 2
9-12 MONTHS
189 K USD 1
Bought
0 USD 0
0-3 MONTHS
314 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 1 week ago
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 week ago
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success. zacks.com - 1 week ago
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript) CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started. seekingalpha.com - 1 week ago
The Best Stocks to Invest $1,000 in Right Now Are you just as afraid of a market pullback right now as you are of missing out on upside? If so, you're not alone. fool.com - 1 week ago
CRISPR Therapeutics to Participate in Upcoming Investor Conferences ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair's 45 th Annual Growth Stock Conference Date: Tuesday, June 3, 2025Time: 11:20 a.m. globenewswire.com - 2 weeks ago
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 3 weeks ago
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies. zacks.com - 3 weeks ago
5 Monster Stocks to Hold for the Next 10 Years The professionals who manage Wall Street funds and cater to wealthy investors live and die by their quarterly performance. However, the individual investor can win the long game by focusing on what will matter the most years into the future. fool.com - 3 weeks ago
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? Shares of gene therapy specialist, CRISPR Therapeutics (CRSP -0.34%) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first treatment from the Food and Drug Administration (FDA), but the stock price is way down. fool.com - 3 weeks ago
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years Despite making significant clinical progress, CRISPR Therapeutics (CRSP 6.83%) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. fool.com - 4 weeks ago
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way. marketbeat.com - 1 month ago
8. Profile Summary

CRISPR Therapeutics AG CRSP

image
COUNTRY CH
INDUSTRY Biotechnology
MARKET CAP $ 3.6 B
Dividend Yield 0.00%
Description CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Contact Baarerstrasse 14, Zug, 6300 https://www.crisprtx.com
IPO Date Oct. 19, 2016
Employees 393
Officers Dr. Daniel G. Anderson Ph.D. Scientific Founder & Advisory Board Member Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member Dr. Raju Yashaswi Prasad Ph.D. Chief Financial Officer Dr. Samarth Kulkarni Ph.D. Chief Executive Officer & Chairman Mr. James R. Kasinger J.D. General Counsel & Secretary Dr. Naimish Patel C.M., M.D. Chief Medical Officer Mr. Shaun Foy CFA Founder Dr. Emmanuelle Marie Charpentier Ph.D. Co-Founder & Scientific Advisory Board Member Dr. Chad A. Cowan Ph.D. Scientific Founder